Company Profile for AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Company:

AlloVir

 

 

Headquarters Address:

139 Main Street

 

Suite 500

 

Cambridge, MA 02142

 

 

Main Telephone:

617-433-2605

 

 

Website:

www.allovir.com

 

 

Ticker/ISIN:

ALVR(NASDAQ)/US0198181036

 

 

Type of Organization:

Public

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: David Hallal

 

CFO: Vikas Sinha

 

 

Investor Relations

 

Contact:

Medha Chadha

Phone:

917-765-2125

Email:

Mchadha@allovir.com

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!